cached image

William Pao - Publications

Affiliations: 
2004-2009 Memorial Sloan-Kettering Cancer Center, Rockville Centre, NY, United States 
 2006-2009 Weill Cornell Medical College, New York, NY, United States 
 2009- Vanderbilt University Medical School 
 2014- Roche Pharma 
Area:
Oncology, Molecular Biology, Biochemistry
Website:
https://medicine.mc.vanderbilt.edu/hemonc_pao

157 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Horn L, Gettinger S, Camidge DR, Smit EF, Janjigian YY, Miller VA, Pao W, Freiwald M, Fan J, Wang B, Chand VK, Groen HJM. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung Cancer (Amsterdam, Netherlands). 113: 51-58. PMID 29110849 DOI: 10.1016/j.lungcan.2017.08.014  1
2017 Arbour KC, Kris MG, Riely GJ, Ni A, Beal K, Daras M, Hayes SA, Young RJ, Rodriguez CR, Ahn L, Pao W, Yu HA. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer. PMID 28940498 DOI: 10.1002/cncr.30990  1
2017 Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, Ye F, Kulick A, De Stanchina E, McEwen R, Ladanyi M, Cross D, Pao W, Lovly CM. SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer. Cancer Research. PMID 28416483 DOI: 10.1158/0008-5472.CAN-16-2300  1
2017 Hartmaier RJ, Charo J, Fabrizio D, Goldberg ME, Albacker LA, Pao W, Chmielecki J. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. Genome Medicine. 9: 16. PMID 28231819 DOI: 10.1186/s13073-017-0408-2  1
2017 Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms Tumors. Molecular Oncology. PMID 28188683 DOI: 10.1002/1878-0261.12044  1
2016 Davidson NE, Armstrong SA, Coussens LM, Cruz-Correa MR, DeBerardinis RJ, Doroshow JH, Foti M, Hwu P, Kensler TW, Morrow M, Mulligan CG, Pao W, Platz EA, Smith TJ, Willman CL. AACR Cancer Progress Report 2016. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: S1-S137. PMID 27697776 DOI: 10.1158/1078-0432.CCR-16-1993  0.01
2016 Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen I, Scheel A, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, ... ... Pao W, et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27252416 DOI: 10.1158/1078-0432.CCR-15-1915  1
2016 Siu LL, Lawler M, Haussler D, Knoppers BM, Lewin J, Vis DJ, Liao RG, Andre F, Banks I, Barrett JC, Caldas C, Camargo AA, Fitzgerald RC, Mao M, Mattison JE, ... Pao W, et al. Facilitating a culture of responsible and effective sharing of cancer genome data. Nature Medicine. 22: 464-71. PMID 27149219 DOI: 10.1038/nm.4089  1
2016 Gao SP, Chang Q, Mao N, Daly LA, Vogel R, Chan T, Liu SH, Bournazou E, Schori E, Zhang H, Red Brewer M, Pao W, Morris L, Ladanyi M, Arcila M, et al. JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. Science Signaling. 9: ra33. PMID 27025877 DOI: 10.1126/scisignal.aac8460  1
2016 Heist RS, Shim HS, Gingipally S, Mino-Kenudson M, Le L, Gainor JF, Zheng Z, Aryee M, Xia J, Jia P, Jin H, Zhao Z, Pao W, Engelman JA, Iafrate AJ. MET Exon 14 Skipping in Non-Small Cell Lung Cancer. The Oncologist. PMID 27022036 DOI: 10.1634/theoncologist.2015-0510  1
2016 Warner JL, Wang L, Pao W, Sosman JA, Atreya RV, Carney P, Levy MA. CUSTOM-SEQ: A Prototype for Oncology Rapid Learning in a Comprehensive EHR Environment. Journal of the American Medical Informatics Association : Jamia. PMID 27008846 DOI: 10.1093/jamia/ocw008  1
2016 Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Research. PMID 26744526 DOI: 10.1158/0008-5472.CAN-15-0717  1
2016 Wang Z, Seow WJ, Shiraishi K, Hsiung CA, Matsuo K, Liu J, Chen K, Yamji T, Yang Y, Chang IS, Wu C, Hong YC, Burdett L, Wyatt K, Chung CC, ... ... Pao W, et al. Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. Human Molecular Genetics. PMID 26732429 DOI: 10.1093/hmg/ddv494  0.01
2015 Liu LL, Li F, Pao W, Michor F. Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients. Plos One. 10: e0141665. PMID 26536620 DOI: 10.1371/journal.pone.0141665  1
2015 Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, Lan Q, Abnet CC, Amundadottir LT, Figueroa JD, Landi MT, Mirabello L, Savage SA, Taylor PR, Vivo ID, ... ... Pao W, et al. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. Journal of the National Cancer Institute. 107. PMID 26464424 DOI: 10.1093/jnci/djv279  0.01
2015 Pirazzoli V, Ayeni D, Meador CB, Sanganahalli B, Hyder F, de Stanchina E, Goldberg SB, Pao W, Politi K. Afatinib plus cetuximab delays resistance compared to single agent erlotinib or afatinib in mouse models of TKI-naïve EGFR L858R-induced lung adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26341921 DOI: 10.1158/1078-0432.CCR-15-0620  1
2015 Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Informatics. 14: 19-31. PMID 26244007 DOI: 10.4137/CIN.S19338  1
2015 Zeng C, Wen W, Morgans AK, Pao W, Shu XO, Zheng W. Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. Jama Oncology. 1: 88-96. PMID 26182310 DOI: 10.1001/jamaoncol.2014.161  0.01
2015 Hutchinson KE, Johnson DB, Johnson AS, Sanchez V, Kuba M, Lu P, Chen X, Kelley MC, Wang Q, Zhao Z, Kris M, Berger MF, Sosman JA, Pao W. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget. PMID 26084293  1
2015 Kawabata S, Hollander MC, Munasinghe JP, Brinster LR, Mercado-Matos JR, Li J, Regales L, Pao W, Jänne PA, Wong KK, Butman JA, Lonser RR, Hansen MR, Gurgel RK, Vortmeyer AO, et al. Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone. Oncotarget. 6: 11357-68. PMID 26027747  1
2015 Galvani E, Sun J, Leon LG, Sciarrillo R, Narayan RS, Tjin Tham Sjin R, Lee K, Ohashi K, Heideman DA, Alfieri RR, Heynen GJ, Bernards R, Smit EF, Pao W, Peters GJ, et al. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor. Oncotarget. PMID 26015408 DOI: 10.18632/oncotarget.3956  1
2015 O'Brien TD, Jia P, Xia J, Saxena U, Jin H, Vuong H, Kim P, Wang Q, Aryee MJ, Mino-Kenudson M, Engelman JA, Le LP, Iafrate AJ, Heist RS, Pao W, et al. Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. Methods (San Diego, Calif.). 83: 118-27. PMID 25913717 DOI: 10.1016/j.ymeth.2015.04.016  1
2015 Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, Meador CB, Spitzler P, Ichihara E, Ross SJ, Ahdesmaki MJ, Ahmed A, Ratcliffe LE, O'Brien EL, Barnes CH, ... ... Pao W, et al. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Research. 75: 2489-500. PMID 25870145 DOI: 10.1158/0008-5472.CAN-14-3167  1
2015 Meador CB, Pao W. Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling. Cancer Discovery. 5: 348-50. PMID 25847954 DOI: 10.1158/2159-8290.CD-15-0221  1
2015 Machiela MJ, Hsiung CA, Shu XO, Seow WJ, Wang Z, Matsuo K, Hong YC, Seow A, Wu C, Hosgood HD, Chen K, Wang JC, Wen W, Cawthon R, Chatterjee N, ... ... Pao W, et al. Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. International Journal of Cancer. Journal International Du Cancer. 137: 311-9. PMID 25516442 DOI: 10.1002/ijc.29393  1
2015 Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, ... ... Pao W, et al. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. Molecular Cancer Therapeutics. 14: 542-52. PMID 25477325 DOI: 10.1158/1535-7163.MCT-14-0723  1
2014 Hutchinson KE, Ross JS, Stephens PJ, Miller VA, Sosman JA, Pao W. Melanoma BRAF fusions--response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6632. PMID 25512636 DOI: 10.1158/1078-0432.CCR-14-1152  1
2014 Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, Chen J, Robinson HE, Shim HS, Chmielecki J, Pao W, Engelman JA, Iafrate AJ, Le LP. Anchored multiplex PCR for targeted next-generation sequencing. Nature Medicine. 20: 1479-84. PMID 25384085 DOI: 10.1038/nm.3729  1
2014 Jia P, Wang Q, Chen Q, Hutchinson KE, Pao W, Zhao Z. MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis. Genome Biology. 15: 489. PMID 25348067 DOI: 10.1186/s13059-014-0489-9  1
2014 Chmielecki J, Hutchinson KE, Frampton GM, Chalmers ZR, Johnson A, Shi C, Elvin J, Ali SM, Ross JS, Basturk O, Balasubramanian S, Lipson D, Yelensky R, Pao W, Miller VA, et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discovery. 4: 1398-405. PMID 25266736 DOI: 10.1158/2159-8290.CD-14-0617  1
2014 Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, ... ... Pao W, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nature Medicine. 20: 1027-34. PMID 25173427 DOI: 10.1038/nm.3667  1
2014 Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA, Pao W. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discovery. 4: 1036-45. PMID 25074459 DOI: 10.1158/2159-8290.CD-14-0326  1
2014 Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nature Reviews. Clinical Oncology. 11: 473-81. PMID 24981256 DOI: 10.1038/nrclinonc.2014.104  1
2014 Kawabata S, Mercado-Matos JR, Hollander MC, Donahue D, Wilson W, Regales L, Butaney M, Pao W, Wong KK, Jänne PA, Dennis PA. Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. Cell Reports. 7: 1824-32. PMID 24931608 DOI: 10.1016/j.celrep.2014.05.039  0.01
2014 Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, ... ... Pao W, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discovery. 4: 1046-61. PMID 24893891 DOI: 10.1158/2159-8290.CD-14-0337  1
2014 Wang R, Wang L, Li Y, Hu H, Shen L, Shen X, Pan Y, Ye T, Zhang Y, Luo X, Zhang Y, Pan B, Li B, Li H, Zhang J, ... Pao W, et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4107-14. PMID 24850843 DOI: 10.1158/1078-0432.CCR-14-0284  1
2014 Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, ... ... Pao W, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama. 311: 1998-2006. PMID 24846037 DOI: 10.1001/jama.2014.3741  1
2014 Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, ... ... Pao W, et al. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Reports. 7: 999-1008. PMID 24813888 DOI: 10.1016/j.celrep.2014.04.014  1
2014 Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, ... ... Pao W, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. The Oncologist. 19: 616-22. PMID 24797823 DOI: 10.1634/theoncologist.2014-0011  1
2014 Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson D, Sosman J, Pao W, Zhao Z. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Molecular Cancer Therapeutics. 13: 1918-28. PMID 24755198 DOI: 10.1158/1535-7163.MCT-13-0804  1
2014 Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Research and Treatment. 145: 389-99. PMID 24722917 DOI: 10.1007/s10549-014-2945-3  1
2014 Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2264-75. PMID 24599935 DOI: 10.1158/1078-0432.CCR-13-1591  1
2014 Jia P, Pao W, Zhao Z. Patterns and processes of somatic mutations in nine major cancers. Bmc Medical Genomics. 7: 11. PMID 24552141 DOI: 10.1186/1755-8794-7-11  1
2014 Wang R, Pan Y, Li C, Zhang H, Garfield D, Li Y, Ye T, Hu H, Luo X, Li H, Zhang Y, Zhang J, Zhou X, Shen L, Pao W, et al. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 760-8. PMID 24481316 DOI: 10.1097/JTO.0b013e3182a406d1  1
2014 Wang Z, Sun Y, Gao B, Lu Y, Fang R, Gao Y, Xiao T, Liu XY, Pao W, Zhao Y, Chen H, Ji H. Two co-existing germline mutations P53 V157D and PMS2 R20Q promote tumorigenesis in a familial cancer syndrome. Cancer Letters. 342: 36-42. PMID 23981578 DOI: 10.1016/j.canlet.2013.08.032  1
2013 Sanders M, Kuba MG, Farley J, Lai D, Su Z, Mayer IA, Means-Powell JA, Vnenzak-Jones C, Levy MA, Pao W, Arteaga CL, Abramson VG. Clinical and pathologic characteristics of patients with PI3K-mutant breast cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 8. PMID 28136604 DOI: 10.1200/jco.2013.31.26_suppl.8  1
2013 Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6696-702. PMID 24345920 DOI: 10.1158/1078-0432.CCR-13-1746  1
2013 Wang Q, Jia P, Li F, Chen H, Ji H, Hucks D, Dahlman KB, Pao W, Zhao Z. Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Medicine. 5: 91. PMID 24112718 DOI: 10.1186/gm495  1
2013 Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, ... ... Pao W, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discovery. 3: 1404-15. PMID 24065731 DOI: 10.1158/2159-8290.CD-13-0314  1
2013 Hosgood HD, Pao W, Rothman N, Hu W, Pan YH, Kuchinsky K, Jones KD, Xu J, Vermeulen R, Simko J, Lan Q. Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. Respiratory Medicine. 107: 1755-62. PMID 24055406 DOI: 10.1016/j.rmed.2013.08.018  1
2013 Red Brewer M, Yun CH, Lai D, Lemmon MA, Eck MJ, Pao W. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: E3595-604. PMID 24019492 DOI: 10.1073/pnas.1220050110  1
2013 Yu HA, Pao W. Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer. Nature Reviews. Clinical Oncology. 10: 551-2. PMID 23959269 DOI: 10.1038/nrclinonc.2013.154  1
2013 Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Research. 23: 1434-45. PMID 23733853 DOI: 10.1101/gr.152322.112  1
2013 Nebhan C, Pao W. Further advances in genetically informed lung cancer medicine. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 521-2. PMID 23584291 DOI: 10.1097/JTO.0b013e31828f583c  1
2013 Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, ... ... Pao W, et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2584-91. PMID 23515407 DOI: 10.1158/1078-0432.CCR-12-3173  1
2013 Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2240-7. PMID 23470965 DOI: 10.1158/1078-0432.CCR-12-2246  1
2013 Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, Sosman JA. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. Ajr. American Journal of Roentgenology. 200: 475-83. PMID 23436834 DOI: 10.2214/AJR.12.9049  1
2013 Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1070-80. PMID 23401451 DOI: 10.1200/JCO.2012.43.3912  1
2013 Red Brewer M, Pao W. Maximizing the benefits of off-target kinase inhibitor activity. Cancer Discovery. 3: 138-40. PMID 23400472 DOI: 10.1158/2159-8290.CD-12-0581  1
2013 Yeh P, Chen H, Andrews J, Naser R, Pao W, Horn L. DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1894-901. PMID 23344264 DOI: 10.1158/1078-0432.CCR-12-1894  1
2013 Wang Q, Xia J, Jia P, Pao W, Zhao Z. Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives. Briefings in Bioinformatics. 14: 506-19. PMID 22877769 DOI: 10.1093/bib/bbs044  1
2013 Johnson ML, Sima CS, Chaft J, Paik PK, Pao W, Kris MG, Ladanyi M, Riely GJ. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer. 119: 356-62. PMID 22810899 DOI: 10.1002/cncr.27730  1
2013 Brewer MR, Yun CH, Lai D, Lemmon MA, Eck MJ, Pao W. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer (Proceedings of the National Academy of Sciences of the United States of America (2013) 110, 38 (E3595-E3604) DOI: 10.1073/pnas.1220050110) Proceedings of the National Academy of Sciences of the United States of America. 110: 20344. DOI: 10.1073/pnas.1320849110  1
2012 Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, Luo X, Wang L, Li H, Zhang Y, Li F, Lu Y, Lu Q, Xu J, Garfield D, ... ... Pao W, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 4352-9. PMID 23150706 DOI: 10.1200/JCO.2012.44.1477  1
2012 Lan Q, Hsiung CA, Matsuo K, Hong YC, Seow A, Wang Z, Hosgood HD, Chen K, Wang JC, Chatterjee N, Hu W, Wong MP, Zheng W, Caporaso N, Park JY, ... ... Pao W, et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nature Genetics. 44: 1330-5. PMID 23143601 DOI: 10.1038/ng.2456  1
2012 Levy MA, Lovly CM, Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Research. 22: 2101-8. PMID 23019146 DOI: 10.1101/gr.131128.111  1
2012 Foo J, Chmielecki J, Pao W, Michor F. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1583-93. PMID 22982659 DOI: 10.1097/JTO.0b013e31826146ee  1
2012 Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, ... ... Pao W, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 150: 1107-20. PMID 22980975 DOI: 10.1016/j.cell.2012.08.029  1
2012 Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, ... Pao W, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discovery. 2: 922-33. PMID 22956644 DOI: 10.1158/2159-8290.CD-12-0108  1
2012 Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, ... ... Pao W, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics. 44: 1104-10. PMID 22941188 DOI: 10.1038/ng.2396  0.01
2012 Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, Küppers R, Thomas RK. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4682-90. PMID 22912387 DOI: 10.1158/1078-0432.CCR-11-3260  1
2012 Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, ... ... Pao W, et al. BRAFL597 mutations in melanoma are associated with sensitivity to MEK inhibitors Cancer Discovery. 2: 791-797. PMID 22798288 DOI: 10.1158/2159-8290.CD-12-0097  1
2012 Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, ... ... Pao W, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America. 109: E2127-33. PMID 22773810 DOI: 10.1073/pnas.1203530109  1
2012 Yatabe Y, Pao W, Jett JR. Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 775-6. PMID 22722783 DOI: 10.1097/JTO.0b013e318251980b  1
2012 Jia P, Li F, Xia J, Chen H, Ji H, Pao W, Zhao Z. Consensus rules in variant detection from next-generation sequencing data. Plos One. 7: e38470. PMID 22715385 DOI: 10.1371/journal.pone.0038470  1
2012 Oxnard GR, Miller VA, Robson ME, Azzoli CG, Pao W, Ladanyi M, Arcila ME. Screening for germline EGFR T790M mutations through lung cancer genotyping. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1049-52. PMID 22588155 DOI: 10.1097/JTO.0b013e318250ed9d  1
2012 Pao W. New approaches to targeted therapy in lung cancer. Proceedings of the American Thoracic Society. 9: 72-3. PMID 22550248 DOI: 10.1513/pats.201112-054MS  1
2012 Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, ... ... Pao W, et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. Plos One. 7: e35309. PMID 22536370 DOI: 10.1371/journal.pone.0035309  1
2012 Xia J, Wang Q, Jia P, Wang B, Pao W, Zhao Z. NGS catalog: A database of next generation sequencing studies in humans. Human Mutation. 33: E2341-55. PMID 22517761 DOI: 10.1002/humu.22096  1
2012 Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nature Medicine. 18: 349-51. PMID 22395697 DOI: 10.1038/nm.2697  1
2012 Lovly CM, Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Science Translational Medicine. 4: 120ps2. PMID 22323827 DOI: 10.1126/scitranslmed.3003728  1
2012 Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, Luo X, Ye T, Wang R, Hu H, Li H, Wang L, Pao W, Chen H. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1947-53. PMID 22317764 DOI: 10.1158/1078-0432.CCR-11-2511  1
2012 Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, ... ... Pao W, et al. ROS1 rearrangements define a unique molecular class of lung cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 863-70. PMID 22215748 DOI: 10.1200/JCO.2011.35.6345  1
2012 Chmielecki J, Pietanza MC, Aftab D, Shen R, Zhao Z, Chen X, Hutchinson K, Viale A, Kris MG, Stout T, Miller V, Rizvi N, Pao W. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 434-42. PMID 22173702 DOI: 10.1097/JTO.0b013e31823c5aee  1
2012 Li C, Sun Y, Fang R, Han X, Luo X, Wang R, Pan Y, Hu H, Zhang Y, Pao W, Shen L, Ji H, Chen H. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 85-9. PMID 22071781 DOI: 10.1097/JTO.0b013e318234f0a2  1
2012 Chmielecki J, Peifer M, Viale A, Hutchinson K, Giltnane J, Socci ND, Hollis CJ, Dean RS, Yenamandra A, Jagasia M, Kim AS, Davé UP, Thomas RK, Pao W. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. Genes, Chromosomes & Cancer. 51: 54-65. PMID 21938754 DOI: 10.1002/gcc.20930  1
2012 Gong Y, Pao W. EGFR mutant lung cancer. Current Topics in Microbiology and Immunology. 355: 59-81. PMID 21866438 DOI: 10.1007/82_2011_171  1
2011 Ohashi K, Pao W. A new target for therapy in squamous cell carcinoma of the lung. Cancer Discovery. 1: 23-4. PMID 22586316 DOI: 10.1158/2159-8274.CD-11-0069  1
2011 Li C, Fang R, Sun Y, Han X, Li F, Gao B, Iafrate AJ, Liu XY, Pao W, Chen H, Ji H. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. Plos One. 6: e28204. PMID 22140546 DOI: 10.1371/journal.pone.0028204  1
2011 Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 9: S1-32; quiz S33. PMID 22138009  1
2011 Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, Mallick P, Michor F. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Molecular Pharmaceutics. 8: 2069-79. PMID 21995722 DOI: 10.1021/mp200270v  1
2011 Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, Rauh D, Pao W, Thomas RK. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7394-401. PMID 21948233 DOI: 10.1158/1078-0432.CCR-11-1648  1
2011 Azzoli CG, Temin S, Aliff T, Baker S, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, et al. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3825-31. PMID 21900105 DOI: 10.1200/JCO.2010.34.2774  1
2011 Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro-Oncology. 13: 1364-9. PMID 21865399 DOI: 10.1093/neuonc/nor121  1
2011 Riely GJ, Johnson ML, Medina C, Rizvi NA, Miller VA, Kris MG, Pietanza MC, Azzoli CG, Krug LM, Pao W, Ginsberg MS. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1435-7. PMID 21847063 DOI: 10.1097/JTO.0b013e318223c099  1
2011 Oxnard GR, Janjigian YY, Arcila ME, Sima CS, Kass SL, Riely GJ, Pao W, Kris MG, Ladanyi M, Azzoli CG, Miller VA. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib Clinical Cancer Research. 17: 6322-6328. PMID 21831955 DOI: 10.1158/1078-0432.CCR-11-1080  1
2011 Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5530-7. PMID 21775534 DOI: 10.1158/1078-0432.CCR-10-2571  1
2011 Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, ... ... Pao W, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science Translational Medicine. 3: 90ra59. PMID 21734175 DOI: 10.1126/scitranslmed.3002356  1
2011 Johnson ML, Riely GJ, Rizvi NA, Azzoli CG, Kris MG, Sima CS, Ginsberg MS, Pao W, Miller VA. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1128-31. PMID 21623279 DOI: 10.1097/JTO.0b013e3182161508  1
2011 Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Research. 71: 4920-31. PMID 21613408 DOI: 10.1158/0008-5472.CAN-10-3879  1
2011 Rizvi NA, Rusch V, Pao W, Chaft JE, Ladanyi M, Miller VA, Krug LM, Azzoli CG, Bains M, Downey R, Flores R, Park B, Singh B, Zakowski M, Heelan RT, et al. Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3500-6. PMID 21558399 DOI: 10.1158/1078-0432.CCR-10-2102  1
2011 Andrews J, Yeh P, Pao W, Horn L. Molecular predictors of response to chemotherapy in non-small cell lung cancer. Cancer Journal (Sudbury, Mass.). 17: 104-13. PMID 21427554 DOI: 10.1097/PPO.0b013e318213f3cf  1
2011 Li J, Su Z, Ma ZQ, Slebos RJ, Halvey P, Tabb DL, Liebler DC, Pao W, Zhang B. A bioinformatics workflow for variant peptide detection in shotgun proteomics. Molecular & Cellular Proteomics : McP. 10: M110.006536. PMID 21389108 DOI: 10.1074/mcp.M110.006536  1
2011 Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America. 108: 5021-6. PMID 21385943 DOI: 10.1073/pnas.1016140108  1
2011 Sengsayadeth S, Montgomery J, Pao W. T4 or MI? Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 632. PMID 21317744 DOI: 10.1097/JTO.0b013e31820b9c0f  1
2011 Pao W, Girard N. New driver mutations in non-small-cell lung cancer. The Lancet. Oncology. 12: 175-80. PMID 21277552 DOI: 10.1016/S1470-2045(10)70087-5  1
2011 Politi K, Pao W. How genetically engineered mouse tumor models provide insights into human cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2273-81. PMID 21263096 DOI: 10.1200/JCO.2010.30.8304  1
2011 Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, Kris MG, Ginsberg MS, Pao W, Miller VA, Riely GJ. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2521-7. PMID 21248303 DOI: 10.1158/1078-0432.CCR-10-2662  1
2011 Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, Kris MG, Pao W, Miller VA, Ladanyi M. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1169-80. PMID 21248300 DOI: 10.1158/1078-0432.CCR-10-2277  1
2011 Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, Chung CH, Massion PP, Vnencak-Jones CL, Iafrate AJ, Pao W. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. The Journal of Molecular Diagnostics : Jmd. 13: 74-84. PMID 21227397 DOI: 10.1016/j.jmoldx.2010.11.010  1
2011 Janjigian YY, Park BJ, Zakowski MF, Ladanyi M, Pao W, D'Angelo SP, Kris MG, Shen R, Zheng J, Azzoli CG. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 569-75. PMID 21150674 DOI: 10.1097/JTO.0b013e318202bffe  1
2011 Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1616-22. PMID 21135146 DOI: 10.1158/1078-0432.CCR-10-2692  1
2011 Pao W, Iafrate AJ, Su Z. Genetically informed lung cancer medicine. The Journal of Pathology. 223: 230-40. PMID 21125677 DOI: 10.1002/path.2788  1
2010 Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, ... ... Pao W, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine. 2: 62ra93. PMID 21160078 DOI: 10.1126/scitranslmed.3001451  1
2010 Chmielecki J, Pao W. Highly active antitumor therapy (HAATT) for epidermal growth factor receptor-mutant lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5371-3. PMID 21062927 DOI: 10.1158/1078-0432.CCR-10-2405  1
2010 Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews. Cancer. 10: 760-74. PMID 20966921 DOI: 10.1038/nrc2947  1
2010 Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, Pao W, Kris MG, Riely GJ, Heelan RT, Arcila ME, Miller VA. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 1623-9. PMID 20871262 DOI: 10.1097/JTO.0b013e3181ec1531  1
2010 Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H, Ji H. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4616-20. PMID 20855837 DOI: 10.1200/JCO.2010.29.6038  1
2010 Azzoli CG, Baker S, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, et al. [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer. 13: 171-89. PMID 20681066 DOI: 10.3779/j.issn.1009-3419.2010.03.15  1
2010 Chmielecki J, Peifer M, Jia P, Socci ND, Hutchinson K, Viale A, Zhao Z, Thomas RK, Pao W. Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Research. 38: 6985-96. PMID 20587502 DOI: 10.1093/nar/gkq579  1
2010 Gao B, Sun Y, Zhang J, Ren Y, Fang R, Han X, Shen L, Liu XY, Pao W, Chen H, Ji H. Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 1130-5. PMID 20559149 DOI: 10.1097/JTO.0b013e3181e05016  1
2010 Zhao B, Oxnard GR, Moskowitz CS, Kris MG, Pao W, Guo P, Rusch VM, Ladanyi M, Rizvi NA, Schwartz LH. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4647-53. PMID 20534736 DOI: 10.1158/1078-0432.CCR-10-0125  1
2010 Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. Journal of Neuro-Oncology. 99: 283-6. PMID 20146086 DOI: 10.1007/s11060-010-0128-6  1
2010 Girard N, Deshpande C, Azzoli CG, Rusch VW, Travis WD, Ladanyi M, Pao W. Use of epidermal growth factor receptor/kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: Comparison with clinical guidelines Chest. 137: 46-52. PMID 19376842 DOI: 10.1378/chest.09-0325  1
2010 Pao W, Girard N. Clinical applications of kinase inhibitors in solid tumors Handbook of Cell Signaling, 2/E. 2: 615-631. DOI: 10.1016/B978-0-12-374145-5.00082-6  1
2009 Girard N, Deshpande C, Lau C, Finley D, Rusch V, Pao W, Travis WD. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. The American Journal of Surgical Pathology. 33: 1752-64. PMID 19773638 DOI: 10.1097/PAS.0b013e3181b8cf03  1
2009 Horn L, Pao W. EML4-ALK: Honing in on a new target in non-small-cell lung cancer Journal of Clinical Oncology. 27: 4232-4236. PMID 19667260 DOI: 10.1200/JCO.2009.23.6661  1
2009 Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America. 106: 9435-40. PMID 19478061 DOI: 10.1073/pnas.0900571106  1
2009 Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer Proceedings of the American Thoracic Society. 6: 201-205. PMID 19349489 DOI: 10.1513/pats.200809-107LC  1
2008 Marks JL, Golas B, Kirchoff T, Miller VA, Riely GJ, Offit K, Pao W. EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations Journal of Thoracic Oncology. 3: 805. PMID 18594331 DOI: 10.1097/JTO.0b013e31817e4664  1
2008 Lyustikman Y, Momota H, Pao W, Holland EC. Constitutive activation of raf-1 induces glioma formation in mice Neoplasia. 10: 501-510. PMID 18472967 DOI: 10.1593/neo.08206  1
2008 Ladanyi M, Pao W. Lung adenocarcinoma: Guiding EGFR-targeted therapy and beyond Modern Pathology. 21. PMID 18437168 DOI: 10.1038/modpathol.3801018  1
2008 Azzoli CG, Park BJ, Pao W, Zakowski M, Kris MG. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: A time for excitement and equipoise Journal of Thoracic Oncology. 3: 84-93. PMID 18166846 DOI: 10.1097/JTO.0b013e31815efe24  1
2007 Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, Pao W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. Plos Medicine. 4: e294. PMID 17927446 DOI: 10.1371/journal.pmed.0040294  1
2007 Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: Searching for the ideal method - Commentary on Hoshi et al., p. 4974 Clinical Cancer Research. 13: 4954-4955. PMID 17785543 DOI: 10.1158/1078-0432.CCR-07-1387  1
2007 Pao W, Gong Y, Balak M. In response [2] Clinical Cancer Research. 13: 3431. DOI: 10.1158/1078-0432.CCR-07-0513  1
2006 Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 7232-41. PMID 17189394 DOI: 10.1158/1078-0432.CCR-06-0658  1
2006 Pao W. Defining clinically relevant molecular subsets of lung cancer Cancer Chemotherapy and Pharmacology. 58. PMID 17093937 DOI: 10.1007/s00280-006-0310-x  1
2006 Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes & Development. 20: 1496-510. PMID 16705038 DOI: 10.1101/gad.1417406  1
2006 Pao W. Monitoring EGFR-mutant lung cancers by means of the blood Journal of Thoracic Oncology. 1: 199-200.  1
2005 Varmus H, Pao W, Politi K, Podsypanina K, Du YCN. Oncogenes come of age Cold Spring Harbor Symposia On Quantitative Biology. 70: 1-9. PMID 16869733 DOI: 10.1101/sqb.2005.70.039  1
2005 Riely GJ, Pao W. Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: Is timing important? Cancer Biology and Therapy. 4: 1096-1097. PMID 16294020  1
2005 Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinoma Journal of Molecular Diagnostics. 7: 396-403. PMID 16049312  1
2005 Ren GP, Wang TY, Pan QL, Pao W, Huai J. Epidermal growth factor receptor mutations detected in tumors from Chinese "never smokers" with lung adenocarcinoma Chinese Medical Journal. 118: 769-771. PMID 15899142  1
2005 Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions Journal of Clinical Oncology. 23: 2556-2568. PMID 15767641 DOI: 10.1200/JCO.2005.07.799  1
2004 Pao W, Miller VA, Venkamatraman E, Kris MG. Predicting sensitivity of non-small-cell lung cancer to gefitinib: Is there a role for P-Akt Journal of the National Cancer Institute. 96: 1117-1119. PMID 15292378  1
2004 Pao W, Miller VA, Kris MG. 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC) Seminars in Cancer Biology. 14: 33-40. PMID 14757534 DOI: 10.1016/j.semcancer.2003.11.005  1
2003 Cong F, Zhang J, Pao W, Zhou P, Varmus H. A protein knockdown strategy to study the function of β-catenin in tumorigenesis Bmc Molecular Biology. 4. PMID 14516475 DOI: 10.1186/1471-2199-4-10  1
2003 Pao W, Klimstra DS, Fisher GH, Varmus HE. Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance. Proceedings of the National Academy of Sciences of the United States of America. 100: 8764-9. PMID 12857957 DOI: 10.1073/pnas.1133333100  1
1998 Wen L, Barber DF, Pao W, Wong FS, Owen MJ, Hayday A. Primary γδ cell clones can be defined phenotypically and functionally as Th1/Th2 cells and illustrate the association of CD4 with Th2 differentiation Journal of Immunology. 160: 1965-1974. PMID 9469460  1
1997 Passoni L, Hoffman ES, Kim S, Crompton T, Pao W, Dong MQ, Owen MJ, Hayday AC. Intrathymic delta selection events in gammadelta cell development. Immunity. 7: 83-95. PMID 9252122  1
1996 Pao W, Wen L, Smith AL, Gulbranson-Judge A, Zheng B, Kelsoe G, MacLennan ICM, Owen MJ, Hayday AC. γδ T cell help of B cells is induced by repeated parasitic infection, in the absence of other T cells Current Biology. 6: 1317-1325. PMID 8939571  1
1996 Mallick-Wood CA, Pao W, Cheng AM, Lewis JM, Kulkarni S, Bolen JB, Rowley B, Tigelaar RE, Pawson T, Hayday AC. Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America. 93: 9704-9. PMID 8790395  1
1996 Dianda L, Gulbranson-Judge A, Pao W, Hayday AC, MacLennan LCM, Owen MJ. Germinal center formation in mice lacking αβ T cells European Journal of Immunology. 26: 1603-1607. PMID 8766567 DOI: 10.1002/eji.1830260729  1
1996 Wen L, Pao W, Wong FS, Peng Q, Craft J, Zheng B, Kelsoe G, Dianda L, Owen MJ, Hayday AC. Germinal center formation, immunoglobulin class switching, and autoantibody production driven by "non α/β" T cells Journal of Experimental Medicine. 183: 2271-2282. PMID 8642336  1
1995 Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature. 378: 303-6. PMID 7477353 DOI: 10.1038/378303a0  1
1991 Kyes S, Pao W, Hayday A. Influence of site of expression on the fetal γδ T-cell receptor repertoire Proceedings of the National Academy of Sciences of the United States of America. 88: 7830-7833. PMID 1652766  1
Show low-probability matches.